SVB Leerink Maintains Outperform on Chinook Therapeutics, Raises Price Target to $44
SVB Leerink analyst Joseph Schwartz maintains Chinook Therapeutics (NASDAQ:KDNY) with a Outperform and raises the price target from $38 to $44.
Chinook Therapeutics Presents Data From Atrasentan Phase 2 AFFINITY IgA Nephropathy Patient Cohort And Evotec Collaboration At The 59th European Renal Association Congress 2022
Chinook Therapeutics Presents Data from Atrasentan Phase 2 AFFINITY IgA Nephropathy (IgAN) Patient Cohort and Evotec Collaboration at the 59th European Renal Association (ERA) Congress 2022
The AFFINITY IgAN cohort of
The Daily Biotech Pulse: CDC Recommends COVID-19 Boosters For Kids 5-11, Foghorn’s Blood Cancer Trial On Clinical Hold, Bayer Intends To Bow Out From CAR-T Therapy Pact With Atara
Here's a roundup of top developments in the biotech space over the last 24 hours:
38 Stocks Moving In Thursday’s Mid-Day Session
Gainers
NeuroMetrix, Inc. (NASDAQ: NURO) shares climbed 34.6% to $4.1993 after the company announced the FDA has granted De Novo authorization to market the Quell neuromodulation device as an aid for reducing the symptoms of fibromyalgia.
Chinook’s Kidney Disease Candidate Continues To Show Rapid, Sustained Reductions In Biomarkers
Chinook Therapeutics Inc (NASDAQ: KDNY) announced updated interim results from the Phase 1/2 study of BION-1301 in IgA nephropathy (IgAN). IgAN, also…
Chinook Therapeutics Q1 EPS $(0.54) Up From $(0.88) YoY, Sales $2.70M Up From $351.00K YoY
Chinook Therapeutics (NASDAQ:KDNY) reported quarterly losses of $(0.54) per share. This is a 38.64 percent increase over losses of $(0.88) per share from the same period last year. The company reported $2.70 million in
Chinook Therapeutics Q4 EPS $0.14 Up From $(1.24) YoY
Chinook Therapeutics (NASDAQ:KDNY) reported quarterly earnings of $0.14 per share. This is a 111.29 percent increase over losses of $(1.24) per share from the same period last year.
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries.
Wednesdays With Wedbush: Analyst Laura Chico On The State Of Biotech
For most issues in the biotech sector, it was a rough 2021, especially when compared to the gains in the S&P 500 index, Wedbush's Laura Chico said Wednesday on "PreMarket Prep Plus."
Chico, the senior vice president of biotech equity research at the analyst firm, said she attributes the underperformance to a few factors.